Medicus Pharma (NASDAQ:MDCX) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a research note published on Monday morning,Benzinga reports. They currently have a $27.00 price objective on the stock.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Medicus Pharma in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $23.50.

Medicus Pharma Stock Performance

Shares of MDCX opened at $0.52 on Monday. Medicus Pharma has a 1 year low of $0.37 and a 1 year high of $8.94. The company’s 50 day simple moving average is $1.26 and its 200 day simple moving average is $1.86. The company has a market capitalization of $13.29 million, a price-to-earnings ratio of -0.24 and a beta of -1.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in Medicus Pharma during the second quarter valued at about $41,000. Osaic Holdings Inc. raised its holdings in shares of Medicus Pharma by 180.0% in the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after purchasing an additional 9,000 shares during the period. Brave Asset Management Inc. purchased a new position in shares of Medicus Pharma in the 3rd quarter worth about $46,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Medicus Pharma in the 3rd quarter valued at about $59,000. Finally, Private Advisor Group LLC lifted its stake in shares of Medicus Pharma by 3.8% in the 3rd quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after purchasing an additional 5,500 shares in the last quarter.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.